Bausch Health Companies Inc T.BHC

Alternate Symbol(s): BHC

Healthcare

Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (GI), hepatology, neurology and dermatology, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products, and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.

TSX:BHC - Post by User

Bausch Health Companies Inc

<< Previous

Bullboard Posts

Next >>

Post by islandbrookon Sep 14, 2020 9:59am

263 Views

Post# 31552091

Debt Calendar

In its latest quartly report Bausch Health stated that tthere is no debt maturities or manditory amortization of debt until 2023. That gives BHC over 2 years to re-finance usings low cost debt.With earnings of $3.58 in 2020 and even higher earnings in 2021, gives it an extremely low PE of below 4. Currently 7 analysts gives it a target price of $28.56.Thats nearly a double.

<< Previous

Bullboard Posts

Next >>

The top TSX healthcare stocks under $1